No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.2x · 10Y median 1.1x · 67th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2022-09-13.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T20:02:46.345Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Innovage Holding Corp. (INNV) stock was $9.00 as of Oct 6, 2026, 4:00 PM EDT, unchanged from the previous close.
Longer view (total return, dividends reinvested): past 12 months +79.1% · 3-year avg +17.1%/yr · 5-year avg +5.5%/yr
InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities.
Medical - Care Facilities · Denver, CO
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2022-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
0.11
Revenue Est.
$257.23M
Last Quarter Results
EPS
$0.10
vs Estimate
$0.08
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1INNV | $1.22B | $9.00 | +0.00% | +79.14% | +5.55% | N/A | N/A |
| 2CRON | $1.23B | $3.28 | +0.92% | +25.83% | -9.92% | +13.62% | vs INNV |
| 3DMRA | $1.21B | $19.70 | -2.60% | +429.27% | -25.05% | N/A | vs INNV |
| 4OMDA | $1.23B | $20.73 | -1.03% | -4.27% | N/A | N/A | vs INNV |
| 5ORIC | $1.23B | $11.92 | -4.56% | -13.37% | -8.73% | N/A | vs INNV |
| 6TYRA | $1.20B | $20.18 | -3.56% | +52.91% | +9.23% | N/A | vs INNV |
forward FY estimate
20.44
$261.95M
vs Estimate
$238.33M
Consensus Rating
Based on 2 analysts
Average Price Target
$12.00
+33.3% upside
Low
$10.00
Current
$9.00
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.08 | $0.09 | $0.09 | 1 |
| Quarter ending Dec 2026 | $0.09 | $0.10 | $0.10 | 1 |
| Quarter ending Mar 2027 | $0.12 | $0.12 | $0.12 | 1 |
| Quarter ending Jun 2027 | $0.13 | $0.14 | $0.14 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $0.35 | $0.44 | $0.48 | 2 |
| FY 2028 | $0.43 | $0.50 | $0.54 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $255.43M | $257.23M | $259.03M | 2 |
| Quarter ending Dec 2026 | $261.70M | $262.50M | $263.31M | 2 |
| Quarter ending Mar 2027 | $270.83M | $271.82M | $272.81M | 1 |
| Quarter ending Jun 2027 | $281.25M | $282.28M | $283.30M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Jun 30, 2027, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2027 | $1.07B | $1.07B | $1.08B | 2 |
| FY 2028 | $1.15B | $1.16B | $1.17B | 3 |
